Royalty Pharma plc Class A Ordinary Shares RPRX
i
Market dataready · fetched 2026-11-12T02:32:35.814Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-11T22:17:19.673767772Z
FundamentalsSEC EDGAR · ready · as of 2026-09-30 · fetched 2026-11-12T02:32:35.439675+00:00
Royalty Pharma plc Class A Ordinary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 83.23 | 113.2% | 21.0% | 60.81 | 119.9% | 15.4% |
| 25Δ | 80.41 | 102.2% | 17.2% | 62.28 | 129.6% | 14.2% |
| 30Δ | 77.60 | 91.3% | 13.5% | |||
| 35Δ | 74.79 | 80.3% | 9.8% | |||
| 40Δ | 72.31 | 70.9% | 6.5% | 68.26 | 68.4% | 5.4% |
| 45Δ | 71.29 | 68.3% | 5.5% | 69.21 | 61.2% | 4.2% |
| 50Δ | 70.27 | 65.6% | 4.5% | 70.06 | 54.5% | 3.2% |
| 55Δ | 69.46 | 61.8% | 3.7% | 70.39 | 49.9% | 2.7% |
| 60Δ | 68.72 | 57.5% | 3.0% | 70.72 | 45.3% | 2.3% |
| 65Δ | 67.98 | 53.2% | 2.3% | 71.05 | 40.7% | 1.9% |
| 70Δ | 67.22 | 50.2% | 1.7% | 71.38 | 36.2% | 1.5% |
| 75Δ | 66.40 | 49.8% | 1.3% | 71.71 | 31.6% | 1.1% |
| 80Δ | 65.58 | 49.4% | 1.0% | 72.04 | 27.0% | 0.7% |
20Δ
- Pseudo strike
- 83.23
- IV
- 113.2%
- B/E move
- 21.0%
- Pseudo strike
- 60.81
- IV
- 119.9%
- B/E move
- 15.4%
25Δ
- Pseudo strike
- 80.41
- IV
- 102.2%
- B/E move
- 17.2%
- Pseudo strike
- 62.28
- IV
- 129.6%
- B/E move
- 14.2%
30Δ
- Pseudo strike
- 77.60
- IV
- 91.3%
- B/E move
- 13.5%
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- 74.79
- IV
- 80.3%
- B/E move
- 9.8%
- Pseudo strike
- IV
- B/E move
40Δ
- Pseudo strike
- 72.31
- IV
- 70.9%
- B/E move
- 6.5%
- Pseudo strike
- 68.26
- IV
- 68.4%
- B/E move
- 5.4%
45Δ
- Pseudo strike
- 71.29
- IV
- 68.3%
- B/E move
- 5.5%
- Pseudo strike
- 69.21
- IV
- 61.2%
- B/E move
- 4.2%
50Δ
- Pseudo strike
- 70.27
- IV
- 65.6%
- B/E move
- 4.5%
- Pseudo strike
- 70.06
- IV
- 54.5%
- B/E move
- 3.2%
55Δ
- Pseudo strike
- 69.46
- IV
- 61.8%
- B/E move
- 3.7%
- Pseudo strike
- 70.39
- IV
- 49.9%
- B/E move
- 2.7%
60Δ
- Pseudo strike
- 68.72
- IV
- 57.5%
- B/E move
- 3.0%
- Pseudo strike
- 70.72
- IV
- 45.3%
- B/E move
- 2.3%
65Δ
- Pseudo strike
- 67.98
- IV
- 53.2%
- B/E move
- 2.3%
- Pseudo strike
- 71.05
- IV
- 40.7%
- B/E move
- 1.9%
70Δ
- Pseudo strike
- 67.22
- IV
- 50.2%
- B/E move
- 1.7%
- Pseudo strike
- 71.38
- IV
- 36.2%
- B/E move
- 1.5%
75Δ
- Pseudo strike
- 66.40
- IV
- 49.8%
- B/E move
- 1.3%
- Pseudo strike
- 71.71
- IV
- 31.6%
- B/E move
- 1.1%
80Δ
- Pseudo strike
- 65.58
- IV
- 49.4%
- B/E move
- 1.0%
- Pseudo strike
- 72.04
- IV
- 27.0%
- B/E move
- 0.7%
Options history
Table
| Date | IV (%) |
|---|---|
| 28.52% | |
| 27.44% | |
| 26.07% | |
| 28.86% | |
| 26.47% | |
| 23.84% | |
| 28.56% | |
| 27.28% | |
| 26.31% | |
| 28.78% |
Biotechnology
RVMD
Revolution Medicines, Inc., a precision clinical-stage oncology company, is focused on developing therapies to inhibit borderline targets in RAS-addicted cancers. The company is…
More →RXRX
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that decodes biology by integrating technological innovations in biology, chemistry, automation, data…
More →RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of rare genetic…
More →RZLT
Rezolute, Inc., a clinical-stage biopharmaceutical company, develops rare and metabolic disease therapies in the United States. The company is headquartered in Redwood City,…
More →SABS
Description unavailable
More →SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on the use of modified cells as medicines. The company is headquartered in Seattle, Washington.
More →